<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37234173</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseases.</ArticleTitle><Pagination><StartPage>1154058</StartPage><MedlinePgn>1154058</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1154058</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1154058</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To investigate the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection on anti-apolipoprotein A-1 IgG (AAA1) humoral response in immunosuppressed inflammatory rheumatic diseases (IRD) patients.</AbstractText><AbstractText Label="METHODS">This is a nested cohort study from the prospective Swiss Clinical Quality Management registry. A total of 368 IRD patients for which serum samples were available before and after the SARS-CoV2 pandemic were included. Autoantibodies against ApoA-1 (AAA1) and its c-terminal region (AF3L1) were measured in both samples. The exposure of interest was anti-SARS-CoV2 spike subunit 1 (S1) seropositivity measured in the second sample. The effect of SARS-CoV2 infection (anti-S1 seropositivity) on becoming AAA1 or AF3L1 positive and on the change of AAA1 or AF3L1 optical density (OD) between the two samples was tested with multivariable regressions.</AbstractText><AbstractText Label="RESULTS">There were 12 out of 368 IRD patients who were seroconverted against S1. The proportion of patients becoming AF3L1 seropositive was significantly higher in anti-S1-positive patients, compared with anti-S1-negative patients (66.7% versus 21.6%, p = 0.001). Adjusted logistic regression analyses indicated that anti-S1 seroconversion was associated with a sevenfold increased risk of AFL1 seropositivity (odds ratio: 7.4, 95% confidence interval (95% CI): 2.1-25.9) and predicted median increase in AF3L1 OD values (+0.17, 95% CI: 0.08-0.26).</AbstractText><AbstractText Label="CONCLUSIONS">SARS-CoV2 infection is associated with a marked humoral response against the immunodominant c-terminal region of ApoA-1 in IRD patients. The possible clinical impact of AAA1 and AF3L1 antibodies on disease progression, cardiovascular complications, or long COVID syndrome deserves future investigations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Lamacchia, Mongin, Juillard, Antinori-Malaspina, Gabay, Finckh, Pagano and Vuilleumier.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lamacchia</LastName><ForeName>Celine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Geneva University Hospital and Faculty of Medicine, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mongin</LastName><ForeName>Denis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Geneva University Hospital and Faculty of Medicine, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juillard</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antinori-Malaspina</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabay</LastName><ForeName>Cem</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Geneva University Hospital and Faculty of Medicine, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geneva Center for Inflammation Research (GCIR), University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finckh</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Geneva University Hospital and Faculty of Medicine, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geneva Center for Inflammation Research (GCIR), University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagano</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vuilleumier</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016632">Apolipoprotein A-I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016632" MajorTopicYN="N">Apolipoprotein A-I</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012213" MajorTopicYN="Y">Rheumatic Fever</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anti-apolipoprotein A-1 IgG</Keyword><Keyword MajorTopicYN="N">autoantibodies</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">inflammatory rheumatic diseases</Keyword><Keyword MajorTopicYN="N">severe acute respiratory syndrome coronavirus 2</Keyword></KeywordList><CoiStatement>NV and SP are named as co-inventors of the patent related to cter-ApoA-1 peptide &#x201c;Mimetic peptides for prognosis, diagnosis or treatment of a cardiovascular disease&#x201d;, N&#xb0; P1347EP00. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>26</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>26</Day><Hour>12</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37234173</ArticleId><ArticleId IdType="pmc">PMC10206305</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1154058</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Satta N, Frias MA, Vuilleumier N, Pagano S. Humoral immunity against HDL particle: a new perspective in cardiovascular diseases? Curr Pharm Des (2019) 25(29):3128&#x2013;46. doi: 10.2174/1381612825666190830164917</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612825666190830164917</ArticleId><ArticleId IdType="pubmed">31470782</ArticleId></ArticleIdList></Reference><Reference><Citation>Croca S, Bassett P, Chambers S, Davari M, Alber KF, Leach O, et al. . IgG anti-apolipoprotein a-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. Arthritis Res Ther (2015) 17(1):26. doi: 10.1186/s13075-015-0539-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-015-0539-z</ArticleId><ArticleId IdType="pmc">PMC4354753</ArticleId><ArticleId IdType="pubmed">25890187</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinu AR, Merrill JT, Shen C, Antonov IV, Myones BL, Lahita RG. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus (1998) 7(5):355&#x2013;60. doi: 10.1191/096120398678920262</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120398678920262</ArticleId><ArticleId IdType="pubmed">9696140</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiochos P, Marques-Vidal P, Virzi J, Pagano S, Satta N, Bastardot F, et al. . Association between anti-apolipoprotein a-1 antibodies and cardiovascular disease in the general population. Results CoLaus study. Thromb Haemost. (2016) 116(4):764&#x2013;71. doi: 10.1161/ATVBAHA.117.309602</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.117.309602</ArticleId><ArticleId IdType="pubmed">27384400</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagano S, Magenta A, D'Agostino M, Martino F, Barilla F, Satta N, et al. . Anti-ApoA-1 IgGs in familial hypercholesterolemia display paradoxical associations with lipid profile and promote foam cell formation. J Clin Med (2019) 8(12):2035. doi: 10.3390/jcm8122035</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm8122035</ArticleId><ArticleId IdType="pmc">PMC6947407</ArticleId><ArticleId IdType="pubmed">31766415</ArticleId></ArticleIdList></Reference><Reference><Citation>Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM. Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms. Viruses (2019) 11(8):762. doi: 10.3390/v11080762</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11080762</ArticleId><ArticleId IdType="pmc">PMC6723519</ArticleId><ArticleId IdType="pubmed">31430946</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev (2021) 20(4):102792. doi: 10.1016/j.autrev.2021.102792</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102792</ArticleId><ArticleId IdType="pmc">PMC7892316</ArticleId><ArticleId IdType="pubmed">33610751</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanduc D. From anti-SARS-CoV-2 immune responses to COVID-19 via molecular mimicry. Antibodies (Basel) (2020) 9(3):33. doi: 10.3390/antib9030033</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib9030033</ArticleId><ArticleId IdType="pmc">PMC7551747</ArticleId><ArticleId IdType="pubmed">32708525</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe (2020) 27(4):671&#x2013;80 e2. doi: 10.1016/j.chom.2020.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.03.002</ArticleId><ArticleId IdType="pmc">PMC7142693</ArticleId><ArticleId IdType="pubmed">32183941</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagano S, Yerly S, Meyer B, Juillard C, Suh N, Le Terrier C, et al. . SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein a-1. Eur J Clin Invest. (2021) 51(11):e13661. doi: 10.1111/eci.13661</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13661</ArticleId><ArticleId IdType="pmc">PMC8420318</ArticleId><ArticleId IdType="pubmed">34324704</ArticleId></ArticleIdList></Reference><Reference><Citation>L'Huillier AG, Pagano S, Baggio S, Meyer B, Andrey DO, Nehme M, et al. . Autoantibodies against apolipoprotein a-1 after COVID-19 predict symptoms persistence. Eur J Clin Invest. (2022) 52(10):e13818. doi: 10.1111/eci.13818</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13818</ArticleId><ArticleId IdType="pmc">PMC9348059</ArticleId><ArticleId IdType="pubmed">35598178</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuilleumier N, Bas S, Pagano S, Montecucco F, Guerne PA, Finckh A, et al. . Anti-apolipoprotein a-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheumatol (2010) 62(9):2640&#x2013;50. doi: 10.1002/art.27546</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27546</ArticleId><ArticleId IdType="pubmed">20506304</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiochos P, Marques-Vidal P, Virzi J, Pagano S, Satta N, Hartley O, et al. . Impact of CD14 polymorphisms on anti-apolipoprotein a-1 IgG-related coronary artery disease prediction in the general population. Arterioscler Thromb Vasc Biol (2017) 37(12):2342&#x2013;9. doi: 10.1161/ATVBAHA.117.309602</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.117.309602</ArticleId><ArticleId IdType="pubmed">29074586</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuilleumier N, Antiochos P, Marques-Vidal P, Pagano S, Virzi J, Satta N, et al. . Prognostic and therapeutic considerations of antibodies against c-ter apolipoprotein a-1 in the general population. Clin Transl Immunol (2020) 9(12):e1220. doi: 10.1002/cti2.1220</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1220</ArticleId><ArticleId IdType="pmc">PMC7734471</ArticleId><ArticleId IdType="pubmed">33343896</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira PC, Ducret A, Ferber P, Gaertner H, Hartley O, Pagano S, et al. . Definition of human apolipoprotein a-I epitopes recognized by autoantibodies present in patients with cardiovascular diseases. J Biol Chem (2014) 289(41):28249&#x2013;59. doi: 10.1074/jbc.M114.589002</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.589002</ArticleId><ArticleId IdType="pmc">PMC4192480</ArticleId><ArticleId IdType="pubmed">25170076</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdaca G, Noberasco G, Olobardi D, Lunardi C, Maule M, Delfino L, et al. . Current take on systemic sclerosis patients' vaccination recommendations. Vaccines (Basel) (2021) 9(12):1426. doi: 10.3390/vaccines9121426</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9121426</ArticleId><ArticleId IdType="pmc">PMC8708328</ArticleId><ArticleId IdType="pubmed">34960174</ArticleId></ArticleIdList></Reference><Reference><Citation>Strangfeld A, Schafer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. . Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis (2021) 80(7):930&#x2013;42. doi: 10.1136/annrheumdis-2020-219498</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-219498</ArticleId><ArticleId IdType="pmc">PMC7843211</ArticleId><ArticleId IdType="pubmed">33504483</ArticleId></ArticleIdList></Reference><Reference><Citation>Bijlsma JW, Force EC-T. EULAR 2021 updated viewpoints on SARS-CoV-2 vaccination in patients with RMDs: a guidance to answer patients' questions. Ann Rheum Dis (2022) 81(6):786&#x2013;8. doi: 10.1136/annrheumdis-2021-221965</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221965</ArticleId><ArticleId IdType="pubmed">35121591</ArticleId></ArticleIdList></Reference><Reference><Citation>Derksen V, Kissel T, Lamers-Karnebeek FBG, van der Bijl AE, Venhuizen AC, Huizinga TWJ, et al. . Onset of rheumatoid arthritis after COVID-19: coincidence or connected? Ann Rheum Dis (2021) 80(8):1096&#x2013;8. doi: 10.1136/annrheumdis-2021-219859</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-219859</ArticleId><ArticleId IdType="pubmed">33648960</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>